国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2013年
8期
695-697
,共3页
康艾注射液%参芪扶正注射液%原发性中晚期肝癌%肝动脉化疗栓塞术%肝功能025
康艾註射液%參芪扶正註射液%原髮性中晚期肝癌%肝動脈化療栓塞術%肝功能025
강애주사액%삼기부정주사액%원발성중만기간암%간동맥화료전새술%간공능025
Kang'ai injection%Shenqifuzheng injection%Advanced primary liver cancer%Transcatheter arterial chemoembolization%Liver function
目的 探讨康艾注射液、参芪扶正注射液对肝动脉化疗栓塞介入术(transcatheter arterial chemoembolization,TACE)后原发性中晚期肝癌患者肝功能的影响.方法 选择2008年12月至2010年12月石家庄市第三医院肿瘤科原发性中晚期肝癌患者120例,按随机数字表法将患者随机分为3组各40例,3组患者均行肝动脉化疗栓塞术,对照组于术后给予抗感染、抑酸、保肝及对症等辅助治疗,保肝药物选用舒肝宁(贵州瑞和制药有限公司),20 ml/1次·d-1;在对照组治疗基础上康艾组静滴康艾注射液40 ml,参芪组静滴参芪扶正注射液250 ml,自介入术当日起共治疗15d.三组患者分别于介入术前及介入术后第3天、第7天、第14天化验肝功能并进行比较.结果 介入术后第14天,参芪组与康艾组的谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBiL)、总胆汁酸(TBA)[参芪组分别为(40.35±10.10)μmol/L、(37.52±10.57) μmol/L、(40.13±8.36) μmol/L、(45.19±19.65) μmol/L;康艾组分别为(40.11±7.31) μmol/L、(34.99±9.38) μmol/L、(32.15±6.58) μmol/L、(40.75±6.79) μmol/L]与对照组[分别为(61.28±13.38) μmol/L、(57.53±13.36)μmol/L、(68.69±7.25)μmol/L、(67.75±17.88) μmol/L]比较,差异有统计学意义(P＜0.01).结论 康艾注射液、参芪扶正注射液分别与TACE联合治疗原发性中晚期肝癌,均可减轻TACE术后肝功能损伤.
目的 探討康艾註射液、參芪扶正註射液對肝動脈化療栓塞介入術(transcatheter arterial chemoembolization,TACE)後原髮性中晚期肝癌患者肝功能的影響.方法 選擇2008年12月至2010年12月石傢莊市第三醫院腫瘤科原髮性中晚期肝癌患者120例,按隨機數字錶法將患者隨機分為3組各40例,3組患者均行肝動脈化療栓塞術,對照組于術後給予抗感染、抑痠、保肝及對癥等輔助治療,保肝藥物選用舒肝寧(貴州瑞和製藥有限公司),20 ml/1次·d-1;在對照組治療基礎上康艾組靜滴康艾註射液40 ml,參芪組靜滴參芪扶正註射液250 ml,自介入術噹日起共治療15d.三組患者分彆于介入術前及介入術後第3天、第7天、第14天化驗肝功能併進行比較.結果 介入術後第14天,參芪組與康艾組的穀丙轉氨酶(ALT)、穀草轉氨酶(AST)、總膽紅素(TBiL)、總膽汁痠(TBA)[參芪組分彆為(40.35±10.10)μmol/L、(37.52±10.57) μmol/L、(40.13±8.36) μmol/L、(45.19±19.65) μmol/L;康艾組分彆為(40.11±7.31) μmol/L、(34.99±9.38) μmol/L、(32.15±6.58) μmol/L、(40.75±6.79) μmol/L]與對照組[分彆為(61.28±13.38) μmol/L、(57.53±13.36)μmol/L、(68.69±7.25)μmol/L、(67.75±17.88) μmol/L]比較,差異有統計學意義(P＜0.01).結論 康艾註射液、參芪扶正註射液分彆與TACE聯閤治療原髮性中晚期肝癌,均可減輕TACE術後肝功能損傷.
목적 탐토강애주사액、삼기부정주사액대간동맥화료전새개입술(transcatheter arterial chemoembolization,TACE)후원발성중만기간암환자간공능적영향.방법 선택2008년12월지2010년12월석가장시제삼의원종류과원발성중만기간암환자120례,안수궤수자표법장환자수궤분위3조각40례,3조환자균행간동맥화료전새술,대조조우술후급여항감염、억산、보간급대증등보조치료,보간약물선용서간저(귀주서화제약유한공사),20 ml/1차·d-1;재대조조치료기출상강애조정적강애주사액40 ml,삼기조정적삼기부정주사액250 ml,자개입술당일기공치료15d.삼조환자분별우개입술전급개입술후제3천、제7천、제14천화험간공능병진행비교.결과 개입술후제14천,삼기조여강애조적곡병전안매(ALT)、곡초전안매(AST)、총담홍소(TBiL)、총담즙산(TBA)[삼기조분별위(40.35±10.10)μmol/L、(37.52±10.57) μmol/L、(40.13±8.36) μmol/L、(45.19±19.65) μmol/L;강애조분별위(40.11±7.31) μmol/L、(34.99±9.38) μmol/L、(32.15±6.58) μmol/L、(40.75±6.79) μmol/L]여대조조[분별위(61.28±13.38) μmol/L、(57.53±13.36)μmol/L、(68.69±7.25)μmol/L、(67.75±17.88) μmol/L]비교,차이유통계학의의(P＜0.01).결론 강애주사액、삼기부정주사액분별여TACE연합치료원발성중만기간암,균가감경TACE술후간공능손상.
Objective To investigate the effect of Kang' ai injection and Shenqifuzheng injection on liver function of patients with advanced primary liver cancer after being performed transcatheter arterial chemomembolization (TACE).Methods 120 patients with advanced primary liver cancer were randomly divided into three groups:a control group,a Kang'ai injection group,and a Shenqifuzheng injection group,with 40 patients in each group.All three groups were treated with TACE,and after TACE the control group was treated with anti-infection,inhibiting-acid,protecting-liver function and Shuganning tablets,20 ml/day.On this basis,the Kang'ai injection group was additionally injected with Kang'ai injection,40ml/day,and Shenqifuzheng injection group was additionally injected with Shenqifuzheng injection,250ml/day.All three groups were treated for 15 days.Liver function was tested and compared at the 3rd day,the 7th day and 14th day after TACE in all three groups.Results At the 14th day after TACE,ALT,AST,TBiL,and TBA of the Kang' ai group and Senqifuzheng group [(40.35 ± 10.10) μmol/L、(37.52 ± 10.57) μmol/L、(40.13 ± 8.36) μmol/L、(45.19 ± 19.65) μmol/L in Senqifuzheng group; (40.11 ±7.31) μmol/L,(34.99±9.38) μmol/L,(32.15±6.58) μmol/L,(40.75 ± 6.79) μmol/L in Kang'ai group] were greatly improved than the control group [(61.28 ± 13.38) μmol/L,(57.53 ± 13.36) μmol/L,(68.69± 7.25) μmol/L,(67.75 ± 17.88) μmol/L],with statistical significance (P＜ 0.01).Conclusion Kang'ai injiection and Shenqifuzhcng injection both can reduce liver function damage caused by TACE,thus they can be used together with TACE for treating advanced primary liver cancer.
